Precigen Reports Positive Long-Term Follow-Up Data for FDA-Approved RRP Therapy, PAPZIMEOS

Precigen Inc. (NASDAQ:PGEN) is one of the hot stocks to buy with huge upside potential. On October 13, Precigen announced long-term follow-up data for PAPZIMEOS (zopapogene imadenovec-drba), which is an immunotherapy for the treatment of adults with recurrent respiratory papillomatosis/RRP. PAPZIMEOS received full approval from the US FDA in August this year, becoming the first and only approved therapy for adult RRP.

The FDA approval was supported by results from a pivotal study, which demonstrated that 51% of the 35 study patients achieved a complete response, defined as requiring no surgeries in the 12 months following treatment with PAPZIMEOS.

PAPZIMEOS (zopapogene imadenovec-drba) is the first and only approved therapy that addresses the root cause of RRP. It is a non-replicating adenoviral vector-based immunotherapy developed using Precigen’s proprietary AdenoVerse therapeutic platform. The drug is designed to express a fusion antigen composed of selected regions of human papillomavirus/HPV types 6 and 11 proteins, which are the causative agents of RRP, to generate an immune response against them.

Precigen Inc. (NASDAQ:PGEN) is a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in areas of immuno-oncology, autoimmune disorders, and infectious diseases.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.